1 / 2

LAC (32%)

Frequency of RAS gene mutation in selected human cancers .*. 1. <1. 3. 1. 14. 45. 55. 99. 98. 86. 96. PDAC (88%). MM (43%). LAC (32%). CRC (52%). 2. 14. 4. 27. 94. 59. Melanoma (28%). Thyroid (13%). Endometrial (25%). Stomach (12%). AML (11%). 9. 5. 21. 30. 57. 58.

darius
Download Presentation

LAC (32%)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Frequency of RAS gene mutation in selected human cancers.* 1 <1 3 1 14 45 55 99 98 86 96 PDAC (88%) MM (43%) LAC (32%) CRC (52%) 2 14 4 27 94 59 Melanoma (28%) Thyroid (13%) Endometrial (25%) Stomach (12%) AML (11%) 9 5 21 30 57 58 21 13 86 Breast (2%) HNSCC (6%) Bladder (11%) KRAS NRAS HRAS *See next slide for key / references.

  2. Figure 1. Frequency of RAS gene mutation in selected human cancers. The overall frequency of all RAS mutations found in each cancer subtype is indicated in parentheses (%), with specific percentage of each RAS gene mutation indicated with the pie charts. Data were compiled from Cancer Cell Line Encyclopedia (CCLE; http://www.broadinstitute.org/ccle), the International Cancer Genome Consortium (ICGC; http://icgc.org) and The Cancer Genome Atlas Data Portal (TCGA; https://tcga-data.nci.nih.gov/tcga/). Cancer subtypes indicated are uterine corpus endometrioid carcinoma, thyroid carcinoma, stomach adenocarcinoma, bladder urothelial carcinoma and breast carcinoma. Abbreviations used are: AML, acute myeologenous leukemia; CRC, colorectal cancer; HNSCC, head and neck squamous cell carcinoma; LAC, lung adenocarcinoma; MM, multiple myeloma; and PDAC, pancreatic ductal adenocarcinoma.

More Related